The global transcatheter aortic valve replacement market is estimated to grow over the forecast period due to increasing incidence of aortic valve stenosis (AS), growing demand for minimally invasive procedures, and the aging population.
According to a February 2023 article from NCBI, aortic stenosis is a structural heart condition characterized by a hemodynamic obstruction at the aortic valve, which hinders blood flow. Among its various causes, calcific aortic stenosis (CAS) is the most prevalent, affecting an estimated 12.6 million people globally.
This represents a high prevalence rate of 1,841 cases per 100,000 individuals in adults aged 70 and older, highlighting its significant impact on the aging population. The rising geriatric population worldwide is another major factor driving transcatheter aortic valve replacement market share.
Older population is at higher risk for cardiovascular conditions such as aortic valve stenosis, which requires efficient management in the form of transcatheter aortic valve replacement. According to a World Health Organization article released in October 2024, the global population aged 60 and older is expected to double by 2050, reaching approximately 2.1 billion.
Additionally, the number of individuals aged 80 and above is projected to triple between 2020 and 2050, reaching about 426 million. This demographic shift indicates a growing need for medical treatment for age-related conditions such as aortic valve stenosis. Since elderly patients are often at higher risk for traditional surgical procedures, the less invasive transcatheter aortic valve replacement offers a safer and more suitable alternative for this population.
Transcatheter aortic valve replacement devices are being employed in minimally invasive aortic stenosis treatment, which is fueling market growth. For instance, in July 2023, Onecera Medical marked a milestone by successfully implanting its crea aortic valve, a transcatheter aortic valve replacement device. The innovative concave-convex shape of the crea aortic valve offers a safe and stable positioning within the aortic annulus.
Additionally, its advanced differential radial force technology promises to enhance performance and patient outcomes by adjusting radial forces based on the valve's position within the annulus and aorta. Furthermore, ongoing innovations in TAVR procedures are crucial to the market's growth. Advancements in valve design, catheter technology, and imaging techniques have all contributed to improved safety and effectiveness.
Improvements in valve design, catheter technologies, and imaging techniques have enhanced the safety, effectiveness, and convenience of transcatheter aortic valve replacement procedures. For instance, Abbott stated in January 2023 that the U.S. FDA approved its latest transcatheter aortic valve replacement system, Navitor, to treat patients with severe aortic stenosis at high risk of open-heart surgery.
New imaging technologies, such as 3D echocardiography and CT scans, enables precise planning and execution of the procedure with less complications. In addition, advancements in catheter technology have led to the development of more compact and flexible catheters, making the procedure even less invasive.
These advancements improve patient outcomes and broaden the potential patient base by making Transcatheter Aortic Valve Replacement a viable option for individuals who were previously considered unsuitable for the procedure.
Mergers and acquisitions in the transcatheter aortic valve replacement market are moderate. Companies are strategically merging to enhance their technological capabilities, diversify product offerings, and expand their market reach. These efforts foster innovation, drive competition, and ultimately accelerate market growth by improving access to advanced transcatheter aortic valve replacement solutions.
For instance, in February 2024, Edwards Lifesciences has acquired JC Medical adding the company’s advanced Transcatheter aortic valve replacement technology for native aortic regurgitation (AR) to its growing arsenal of structural heart treatments. JC Medical was previously owned by Genesis MedTech, an international medical device company based out of Singapore.
Similarly, in August 2024, Boston Scientific Corporation announced it has obtained CE mark for the ACURATE Prime Aortic Valve System, the newest Transcatheter aortic valve replacement technology in the company's structural heart portfolio.
The ACURATE Prime valve system is designed with several features to build upon the clinical performance of the ACURATE neo2 platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.
Transfemoral segment led the market with 50.6% revenue in 2024. It includes introduction of valve via the femoral artery, providing less invasive compared to open-heart surgery. Advancements in technology, better outcomes from procedures, and widening criteria for patient enrollment spur greater usage of transfemoral valve replacement procedures.
The Elsevier B.V. article of December 2024, in a study conducted recently of 10,120 patients treated with transfemoral Transcatheter Aortic Valve Replacement in 10 centers, 7,165 patients (approximately 71%) preferred TF access.
The strategy remains the option of choice given its excellent outcomes and availability of state-of-the-art technologies to increase procedural safety. Expansion driven by increasing popularity of alternatives like trans-radial secondary access (TR-SA) and TF access also fuels market expansion.
North America was the leader in the market for transcatheter aortic valve replacement and held a 38.7% market share in 2024 due to its established healthcare system and growing number of conditions like aortic stenosis (AS) and aortic regurgitation. Growing prevalence of these disorders will be expected to drive market growth during the forecast period.
As per the American Heart Association, Inc. article published in May 2024, in the United States, the prevalence of aortic stenosis is about 15.6 events per 100 patients, contributing largely to the increasing need for Transcatheter Aortic Valve Replacement (TAVR) procedure.
This high rate of incidence is a major impetus for the transcatheter aortic valve replacement market, as patients and healthcare professionals look for efficient, less invasive treatments to treat this severe condition.
NA
NA
NA
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Transcatheter Aortic Valve Replacement Market
